News

Novo Nordisk and US biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
CEO of Novo Nordisk, maker of Wegovy, is stepping down
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...
Why Novo Nordisk Stock Just Slipped
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
From insulin to Ozempic, history of Novo Nordisk's CEOs
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...
Novo Nordisk Woes Just Hit Denmark’s Economy. The Stock Is Rising.
That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...
Fierce Pharma6h
As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...
Novo Nordisk upgraded to ’AA’ from ’AA-’ by S&P Global Ratings
Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...